sumatriptan succinate / Generic mfg. - LARVOL DELTA

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. (PubMed, Headache) - "Prochlorperazine IV and GONB must be offered to eligible adults presenting to the ED with a migraine attack for treatment of headache requiring parenteral therapy (level A - must offer) in those without contraindications, while hydromorphone IV must not be offered (level A - must not offer). Treatments that should be offered when appropriate (level B - should offer) include dexketoprofen IV, ketorolac IV, metoclopramide IV, sumatriptan SC, and SONB. Chlorpromazine IV, dexamethasone IV, and valproate IV may be offered (level C - may offer). Paracetamol IV may not be offered (level C - should not offer). Eptinezumab should be offered (level B) only for patients matching the clinical trial population but is rated level U - no recommendation for an ED-specific population. Additional evidence is needed for caffeine, granisetron, ibuprofen, ketamine, lidocaine, normal saline, propofol, and SPG blocks, all currently rated level U - no recommendation."

Journal • CNS Disorders • Migraine • Pain

Recurrent severe headache with a background of functional vomiting and normal brain MRI, in paediatric reversible cerebral vasoconstriction syndrome (RCVS) (EHF-EHC 2025) - "Sumatriptan had made his headaches worse...Results After the diagnosis of RCVS, he was started on oral Nimodipine and his headaches events reduce in frequency and severity to once a day...RCVS is easily mistaken for status migranosus. Triptan treatment could potentially worsen this condition due to vasoconstriction as part of its mode of action."

Cardiovascular • Chronic Kidney Disease • CNS Disorders • Cognitive Disorders • Migraine • Pain • Pediatrics

Behavioural characterisation of a codeine-induced medication overuse headache model in mice: Focus on pain-related behaviour and cognitive impairment (EHF-EHC 2025) - "After the 12-day drug-free period (day 21), we assessed the development of periorbital allodynia following application of a low nitroglycerin dose. Codeine induced cutaneous allodynia and cognitive impairment in mice, with effects comparable to those of sumatriptan. These results support the idea of codeine-induced model of MOH as a promising preclinical tool for studying MOH and its consequences."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Migraine • Pain

Refractory chronic cluster headache: A new therapeutic option (EHF-EHC 2025) - "Acute therapy with oral zolmitriptan 5 mg, subcutaneous sumatriptan 6 mg, and oxygen were used, with moderate effect. Preventive treatment included prednisolone and occipital nerve block during exacerbations, and verapamil, both as monotherapy and in combination with topiramate and lithium in various regimens...Treating refractory chronic cluster headache is challenging, as it is highly disabling for the patient. Although other therapies targeting CGRP have not shown clear benefit in clinical trials, especially in chronic forms, atogepant may offer a promising alternative."

Anorexia • Cardiovascular • Chronic Cluster Headache • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Hypertension • Migraine • Pain

Clinical-genotype machine prescription for migraine – A HUNT study (EHF-EHC 2025) - "In total, 475 participants tried a preventive (amitriptyline, beta-blocker, candesartan or topiramate) and 565 a triptan (371 sumatriptan) during the project period. Figure 1 . SHAP bar blot of ten most important clinical features across all four preventive models"

Clinical • CNS Disorders • Migraine • Pain

Pharmacokinetics and safety of Lu AG09222, an anti-PACAP monoclonal antibody in development for migraine prevention (EHF-EHC 2025) - "Data were included from a (1) first-in-human single ascending dose trial in healthy participants, including a cohort with co-administered sumatriptan (Lu AG09222 n=68; placebo n=28); (2) single-dose trial in healthy Caucasian, Chinese, and Japanese participants (Lu AG09222 n=40; placebo n=12); and (3) multiple-dose trial in participants with symptomatic allergic rhinitis (Lu AG09222 n=20; placebo n=10). Lu AG09222 exhibited a consistent PK profile across dosing regimens, route of administration and race/ethnicity. Across these trials, no safety concerns were identified, and Lu AG09222 was generally well-tolerated."

Clinical • PK/PD data • Allergic Rhinitis • CNS Disorders • Immunology • Inflammation • Migraine • Pain • ADCYAP1

Comparative analysis of efficacy between sumatriptan and naratriptan in the abortive treatment of migraine (EHF-EHC 2025) - "Therefore, factors such as time to pain relief, duration of effect, recurrence rate of attacks, and cardiovascular adverse effects should be considered. Thus, the choice between the two medications should be made based on the patient's profile and clinical needs for attack control, considering both efficacy and safety profile."

Clinical • Cardiovascular • CNS Disorders • Migraine • Pain

Paracetamol (Acetaminophen) and caffeine combination in headache management (EHF-EHC 2025) - "Two other TTH clinical trials have shown that the efficacy and safety of combination was comparable to Naproxen 550 mg and Ibuprofen 400 mg. One randomized, cross-over trial has shown a comparable efficacy/safety profile of the combination vs sumatriptan 50 mg in treatment of migraine attack. No data are available on the risk of medication overuse with the combination compared to paracetamol alone. Caffeine accelerates and prolongs the analgesic effect of paracetamol over time with a significant improvement of pain relief in patients with primary headaches without added safety issues."

CNS Disorders • Migraine • Pain • ADORA2A

Arc-mediated synaptic plasticity regulates cognitive function in a migraine mouse model (EHF-EHC 2025) - "C57BL/6 mice were randomly divided into four groups: the IS group (migraine model induced by inflammatory soup, IS), IS+M group (IS model + memantine treatment), IS+S group (IS model + sumatriptan treatment), and a control group (PBS with no IS stimulation). Cognitive dysfunction in the migraine model was associated with impaired synaptic plasticity, as indicated by reduced Arc expression. Memantine treatment alleviated cognitive deficits and restored synaptic function, suggesting that Arc-mediated synaptic plasticity may play a critical role in migraine-related cognitive impairment and could be a potential therapeutic target."

Preclinical • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Migraine • Pain

Does heterogeneity in patient population, study design, and endpoint definitions affect indirect comparisons of acute migraine treatments? A methodological assessment (EHF-EHC 2025) - "[6] who reported changes in the relative effect of sumatriptan over time. ITCs of acute migraine trials, sometimes conducted decades apart, acknowledge heterogeneity but did not attempt to statistically adjust for it. More sophisticated analytical approaches are needed to obtain unbiased and reliable estimates of indirect comparative effectiveness."

Clinical • Heterogeneity • CNS Disorders • Migraine • Pain

A review on gut microbiota and migraine severity: a complex relationship. (PubMed, Inflammopharmacology) - "It is worth noting that research highlights several innovative treatments for migraine, such as Zelirex and Cevimide, implantable devices like Cefaly and Revilion, and new effective routes of administration for Sumatriptan. Finally, patients' perspectives and concerns were thoroughly discussed, with a focus on future directions in the migraine-gut axis research."

Journal • Review • CNS Disorders • Gastrointestinal Disorder • Migraine • Pain

Effects of Olcegepant, Sumatriptan, and Ibuprofen on Migraine-Like Behavior Induced by Repetitive Restraint Stress in Mice (Neuroscience 2025) - "These injections were repeated for sumatriptan on Day 3, while olcegepant was injected on Day 2, and Day 3. We showed that restraint stress can cause migraine-like behaviors that are responsive to several migraine therapeutics. These data further validate this model as being translationally relevant for testing migraine therapeutics and they provide insight into the mechanisms by which stress causes behavioral features consistent with migraine."

Preclinical • CNS Disorders • Migraine • Pain

Characterization of the isosorbide dinitrate model of headache in male and female rats (Neuroscience 2025) - "Pretreatment with the mu opioid receptor agonist morphine sulfate (0.3, 1, 3, and 6 mg/kg, SC), 5-HT1B/1D agonist sumatriptan (0.1, 0.3 and 1 mg/kg, IP), CGRP receptor antagonist olcegepant (0.3, 1, and 3 mg/kg, IP), and delta opioid receptor agonist SNC80 (3, 10, and 30 mg/kg, SC) suppressed the development of ISDN-induced facial allodynia in a dose-dependent manner. Additionally, we are planning to evaluate non-evoked behavioral pain endpoints (i.e. orbital tightening) and altered sensitivity associated with migraine (i.e. photophobia/phonophobia) to further characterize this model. The data to date support the use of this model to identify potential treatments for headache disorders as part of the NIH HEAL initiative to identify novel, non-opioid treatments for pain."

Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Migraine • Pain

In vivo PK, side effect profile, and analgesic efficacy of clinically used compounds in male and female rats demonstrating the established approach of the NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP) to profile potential novel analgesics. (Neuroscience 2025) - "In efficacy studies, sumatriptan provided minimal improvements on acute mechanical allodynia in the plantar incision and SNL models but did not show efficacy in guarding behavior in the plantar incision model or cold allodynia in the SNL model. The results of these studies of clinically used compounds within the PSPP program demonstrate the validation of the models and endpoints described and highlight the goal of providing a robust platform to accelerate the discovery and preclinical development of non-opioid, non-addictive treatments for pain"

Adverse events • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Population Pharmacokinetics of Atogepant for the Prevention of Migraine. (PubMed, Clin Pharmacokinet) - P3 | "The pharmacokinetics of atogepant are similar in healthy participants and patients with CM or EM. Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycoprotein (P-gp) inhibitors, BCRP inhibitors, oral contraceptive components (ethinyl estradiol and levonorgestrel), famotidine, esomeprazole, sumatriptan, acetaminophen, and naproxen are not necessary. Atogepant's popPK model provides a valuable tool for evaluating specific questions for patients, healthcare providers, and regulatory agencies. Integration into other modeling approaches has also aided in model-informed drug development decisions."

Journal • PK/PD data • Breast Cancer • CNS Disorders • Hepatology • Migraine • Oncology • Pain • Renal Disease • Solid Tumor

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System. (Business Standard) - "The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Imitrex STATdose System, 4 mg/0.5 mL and 6 mg/0.5 mL, of GlaxoSmithKline Intellectual Property Ltd. England. Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache."

ANDA • Migraine • Pain

Characteristics and management of headache among psychiatric outpatients at a Japanese general hospital: A retrospective study with an exploratory CGRP case series. (PubMed, PCN Rep) - "At the agent level, acetaminophen (n = 38), loxoprofen (n = 33), zolmitriptan (n = 14), goreisan (n = 8), sumatriptan (n = 6), kakkonto (n = 6), diclofenac (n = 4), valproic acid (n = 4), and naratriptan (n = 3) were among the most frequently listed. CGRP-targeted therapy yielded headache relief even under psychiatric comorbidity, while psychiatric symptoms did not uniformly improve, underscoring the need for parallel mental-health interventions alongside headache-specific care. Strengthening cross-specialty pathways and early headache evaluation within psychiatry are warranted."

Journal • Retrospective data • Autism Spectrum Disorder • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Genetic Disorders • Mental Retardation • Migraine • Pain • Post-traumatic Stress Disorder • Psychiatry • Rheumatology • Schizophrenia • Social Anxiety Disorder

Susac syndrome and associated diagnostic challenges: a case report. (PubMed, J Med Case Rep) - "This case underscores the diagnostic complexity of Susac syndrome and the importance of considering it in young patients with unexplained persistent headaches progressing to encephalopathy. Early magnetic resonance imaging and timely intervention with immunosuppressive therapy are critical for managing the disease and preventing irreversible sequelae."

Journal • CNS Disorders • Immunology • Migraine • Otorhinolaryngology • Pain • Rare Diseases • Vasculitis

Experimental and thermodynamic modeling of sumatriptan solubility in supercritical carbon dioxide for green pharmaceutical applications. (PubMed, Sci Rep) - "Thermodynamic modeling using the PC-SAFT, Peng-Robinson and Soave-Redlich-Kwong combined with mixing rules showed that the PC-SAFT offered better accuracy (AARD = 11.75%, Radj = 0.988). These findings provide essential experimental data and validated predictive models that are critical for designing eco-friendly supercritical fluid processes, such as the supercritical anti-solvent."

Journal

A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy. (PubMed, J Pain Res) - "The report proportion varied among triptans, with naratriptan (12.23%) and almotriptan (12.15%) showing the highest rates, while sumatriptan (4.74%) had the lowest...Disproportionality analysis revealed significant signals for almotriptan (ROR=3.34), naratriptan (ROR=2.96), and rizatriptan (ROR=2.41), with almotriptan exhibiting the strongest association...Time-to-onset analysis showed frovatriptan had the earliest median onset (3.5 days), while almotriptan had the longest (284 days)...Clinicians should carefully evaluate cardiovascular risk factors before prescribing triptans and consider alternative treatments for susceptible individuals. Additional prospective studies are required to validate these findings."

Adverse events • Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Ischemic stroke • Migraine • Myocardial Infarction • Pain

NON-INVASIVE NEUROMODULATION OF COMORBID MIGRAINE, TRAUMATIC BRAIN INJURY, AND PTSD (WCN 2025) - "Sumatriptan 1-2 times/week. These cases support the benefit of NNM in treating comorbid migraine, PTSD, and TBI."

Non-invasive • CNS Disorders • Insomnia • Migraine • Pain • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder • Vascular Neurology

COMPARATIVE ANALYSIS OF THE EFFICACY BETWEEN SUMATRIPTAN AND NARATRIPTAN IN THE ABORTIVE TREATMENT OF MIGRAINE (WCN 2025) - ": Both SMT and NRT are effective abortive treatments with distinct pharmacodynamic profiles. NRT may offer superior tolerability and sustained efficacy in selected patients, supporting individualized therapeutic decisions."

Clinical • CNS Disorders • Migraine • Pain

Drug-Induced Liver Injury in Undiagnosed POLG-Related Mitochondrial Disease: Implications for Critical Care Management (ASA 2025) - "Her PMHx was significant for migraines, with recent sumatriptan prescription...She ultimately underwent orthotopic liver transplantation and was admitted to the surgical ICU. This case highlights the complexities of postoperative critical care management in a patient with mitochondrial disease."

CNS Disorders • Critical care • Epilepsy • Hepatology • Liver Failure • Metabolic Disorders • Migraine

Identifying metabolism-related genes in liver cancer through weighted gene co-expression network analysis and machine learning. (PubMed, Front Genet) - "Immune infiltration analysis revealed these genes might influence immune cell infiltration in the tumor microenvironment. And the candidate drugs were unveiled, including PAZOPANIB, SUMATRIPTAN, ETOPOSIDE, etc. The metabolism-related biomarkers ACADS, ALDH8A1, COX4I2, CYP2C8, DBH, and NDST3 demonstrated significant potential for predicting liver cancer prognosis and may serve as candidate therapeutic targets."

Journal • Liver Cancer • Metabolic Disorders • Oncology • Solid Tumor

The Association Between Clinical Features and Sumatriptan Responsiveness in Patients with Migraine (IHC 2025) - "Conclusion Our findings suggest that early use of triptans may improve treatment effectiveness, particularly given that sumatriptan unresponsiveness was associated with CM and prior failures of acute analgesics. Furthermore, triptan may still offer therapeutic benefits to patients with medication overuse."

Clinical • CNS Disorders • Migraine